

Laparoscopic Surgery in Early Stage Ovarian Cancer



Jae-Kwan Lee MD, PhD

Korea University College of Medicine, Seoul, Korea

Contents

Introduction

Early stage ovarian cancer

Laparoscopic surgical staging in Gyn cancer

Possible advantage

EBL, Complication, Recovery

Potential disadvantage

Feasibility, Safety, Cost

Summary

Ovarian Cancer in 2012

- **Worldwide**

- Incidence

- New cases: 238,719 (6.8/100,000)

- 8th most common in 2008 → 7th in 2012

- Mortality

- Deaths: 151,905 (4.3/100,000): Ranking 8th

(GLOBOCAN 2012)

- **In Korea**

- Incidence: 8.0/100,000 (in 2011): Ranking 10th

- Mortality: 2.7/100,000: Ranking 8th

Poor Survival in Ovarian Cancer

- In a large data of 1,815,584 patients




Europe, country-weighted observed and relative survival (%), by age at diagnosis (years)

AGE		15-44		45-54		55-64		65-74		75-99		All ages 15-99	
Women		obs	rel	obs	rel	obs	rel	obs	rel	obs	rel	obs	rel
	One year	88	89	83	84	72	73	60	61	35	38	65	66
	Three years	74	74	60	61	45	46	33	35	18	23	42	45
	Five years	69	70	49	50	35	37	25	28	13	20	34	38

➡ Just about 1/3 women are alive 5 years after diagnosis.

Distribution by stage

- Poor survival: Largely because most women are diagnosed when the cancer is **already at an advanced stage**.



Diagnosis in Early Stage

- Diagnosis is usually made by accidental discovery at sonography, CT scanning or during laparoscopy.
- Incidence of accidental discovery at laparoscopy for an adnexal mass
 - 0.65% – 0.9% of premenopausal women
 - 3% of postmenopausal women

J Minim Invasive Gynecol 2005;12:81

Standard Management

- **Intention of surgical staging**
 - To assess the extent of the disease
 - To remove as much gross tumor as possible
- **Surgical Treatment**
 - Comprehensive surgical staging by laparotomy, a midline abdominal incision
 - Includes...
 - total hysterectomy, BSO, cytology, omentectomy, retroperitoneal (pelvic & para-aortic) LN dissection or sampling, biopsy of all suspicious areas including mesentery, liver & diaphragm*

Laparoscopic Surgery



Minimally Invasive Surgery:

always been a hot issue in GY era, now even in GY cancer!

- **Endometrial cancer**

- In a meta-analysis of 8 RCTs:

- “**Laparoscopic approach is safer** than the traditional abdominal approach with particular regard for postoperative complications.”

Am J Obstet Gynecol 2012;207:94

- **Cervical Cancer**

- Recently many studies about laparoscopic radical op.

In Ovarian Malignancies

(1) Borderline ovarian tumor

- Evidence mostly based on retrospective series suggest :
Laparoscopic surgery in BOT *seems feasible and safe.*
- But, BOT is distinct from ovarian cancer
 - Excellent prognosis:
Overall survival: 98% in stage, 92% in advanced stage
 - High proportion of early stage: stage I (50-85%)

(2) Invasive ovarian cancer

Invasive Ovarian Cancer

KUMC

(1) Laparoscopy in early stage

(2) Laparoscopy in advanced stage

- Role of laparoscopy has been primarily described in 4 areas:
 - Triage tool for resectability
 - Second-look surgical evaluation
 - Primary or secondary cytoreduction
 - Insertion of intraperitoneal catheters

J Minim Invasive Gynecol 2009;16:250

-  30 articles about laparoscopy in advanced ovarian cancer



Early Stage Ovarian Cancer

- Stage I ovarian cancer is a rare disease & laparoscopy for staging is a relatively new field of clinical study, so data are scarce.
- ➡ Laparoscopy in ovarian cancer *remains controversial.* & Unclear how the risks & benefits compare with the conventional open approach by laparotomy.
- ➡ Different guideline about standard procedure

Difference in the Guidelines

- **Recent UK Guidelines**

NICE National Institute for
Health and Care Excellence


- **Not consider laparoscopy** as an approach to the surgical staging of early ovarian cancer

- **German Gynecological Oncology Group**



- For selected patients & only when performed by expert laparoscopic oncology surgeons, pending further evidence

NCCN Guidelines Version 3.2014 Epithelial Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer



- In most instances, a vertical midline abdominal incision should be used in patients with a suspected malignant ovarian.
- For select patients, a minimally invasive surgical approach may be employed by an experienced surgeon.


Current Status of Studies

- First report: *Querleu* in 1993
for two women with borderline ovarian tumors
- A meta-analysis (Cochrane review)
 - 2008: No RCTs were identified.
3 observational studies were identified.
 - 2013: This review has found no good-quality evidence.




Meta-analysis

- 1,395 records
- **None** of the comparative studies reported adjusting results for baseline characteristics, considered to be at a high risk of selection bias and other bias
- Summarized the relevant case series, case-control studies, & retrospective cohort studies



Possible Advantages

1. Less blood loss
2. Fewer complications
 - Less postoperative infection



3. Faster recovery
 - Shorter hospital stay, faster return of bowel function
 - Chemotherapy can be commenced sooner
 - ➡ Potentially resulting in a favorable effect on survival ?
4. Smaller incisions ➡ Improve patient's satisfaction ?
5. Laparoscopy image can be magnified.
 - ➡ Better visualization of the tumor inside the abdomen ?

1. Blood Loss

3 Case-control studies & 5 Retrospective cohort of LPS vs. open staging of early ovarian cancer

	Study period	No. Case		Blood loss (ml)			Transfusion (n, %)		
		LPS	LPT	LPS	LPT	<i>P</i>	LPS	LPT	<i>P</i>
<i>Hua 2005</i>	2002-2004	10	11	280 ↓	346	<0.05	-	-	-
<i>Chi 2005</i>	2000-2003	20	30	235 ↓	367	0.003	-	-	-
<i>Ghezzi 2007</i>	2003-2006	15	19	250	400	0.28	1 (6.7)	2 (10.5)	1.0
<i>Park^a 2008</i>	2001-2006	17	19	231 ↓	505	0.001	0	2 (11)	-
<i>Park^b 2008</i>	2004-2007	19	33	240 ↓	569	0.005	1 (5) ↓	10 (30)	0.04
<i>Park 2010[*]</i>	2004-2008	40	76	301 ↓	494	0.004	6 (15)	23 (30)	0.071
<i>Park 2011[*]</i>	2004-2010	84	128	207 ↓	262	<0.001	6 (13) ↓	36 (28)	0.012
<i>Lee 2011</i>	2005-2010	26	87	230 ↓	475	<0.001	0 ↓	20 (23)	0.006

*These studies are expansions of the original data set.

*LPS (laparoscopy) vs. LPT (laparotomy) 17


2. Complication

	Study period	No. Case		Conversion to LPT (n)	(Postop) Complications		
		LPS	LPT		LPS	LPT	<i>P</i>
<i>Hua 2005</i>	2002-2004	10	11	-	2 (20%) ↓	7 (72.7%)	< 0.01
<i>Chi 2005</i>	2000-2003	20	30	0	0	3 (10%)	-
<i>Ghezzi 2007</i>	2003-2006	15	19	0	2 (13.3%)	8 (42.1%)	0.13
<i>Park^a 2008</i>	2001-2006	17	19	0	0	4 (21%)	-
<i>Park^b 2008</i>	2004-2007	19	33	1	2	9	0.290
<i>Park 2011*</i>	2004-2010	84	128	-	6 (7.1%) ↓	25 (20%)	0.013
<i>Lee 2011</i>	2005-2010	26	87		2	20	-

*These studies are expansions of the original data set.


❖ 8 RCTs of Endometrial cancer

A Intraoperative complications



B Post-operative complications

Significant advantage of laparoscopy



3. Recovery

	Return to bowel movement (days)			Hospital stay (days)			Time to Adj CTx (days)		
	LPS	LPT	<i>P</i>	LPS	LPT	<i>P</i>	LPS	LPT	<i>P</i>
<i>Chi 2005</i>	-	-	-	3.1 ↓	5.8	< 0.01	-	-	-
<i>Ghezzi 2007</i>	-	-	-	3 ↓	7	0.001	-	-	-
<i>Park^a 2008</i>	3.8 ↓	2.0	<0.001	9.4 ↓	14.1	0.002	11.1	14.3	0.140
<i>Park^b 2008</i>	1.3 ↓	3.6	<0.001	8.9 ↓	14.5	0.002	12.8 ↓	17.6	0.049
<i>Park 2010[*]</i>	1.7 ↓	3.6	<0.001	7.9 ↓	14.5	0.002	15.8 ↓	20.7	<0.001
<i>Park 2011[*]</i>	1.8 ↓	3.1	<0.001	6.3 ↓	13.5	<0.001	15.8 ↓	20.7	<0.001
<i>Lee 2011</i>	-	-	-	6.4 ↓	12.4	<0.001	8.5 ↓	10.3	0.007

*These studies are expansions of the original data set.

Potential Disadvantages

1. **Feasibility:** Technical challenge

- Longer operating time
- Longer learning curve
- Difficulty in comprehensive surgical staging
 - Particularly LND, Up-staging rate
- Higher rate of intraoperative cyst rupture & tumor spillage

2. **Safety issues**

- Laparoscopy-specific complications
 - Effect of CO₂ for pneumoperitoneum
 - Possibility of port-site metastases
- Insufficient survival data that guarantee the oncologic safety

3. **Higher cost**

1. Operating time

	Study period	No. Case		OP time (min)		
		LPS	LPT	LPS	LPT	P
<i>Hua 2005</i>	2002-2004	10	11	298 ↑	182	<0.05
<i>Chi 2005</i>	2000-2003	20	30	321 ↑	276	0.04
<i>Ghezzi 2007</i>	2003-2006	15	19	377 ↑	272	0.002
<i>Park^a 2008</i>	2001-2006	17	19	303	290	0.706
<i>Park^b 2008</i>	2004-2007	19	33	221 ↓	275	0.012
<i>Park 2010*</i>	2004-2008	40	76	230 ↓	278	0.001
<i>Park 2011*</i>	2004-2010	84	128	207 ↓	262	<0.001
<i>Lee 2011</i>	2005-2010	26	87	228 ↑	184	0.016

Measures of the **technical feasibility** have included:

- LN yields,
- Size of the omental specimen,
- Intra-operative tumor spillage,
- & Operating time.



These differences reflect differences in surgeons' skills & LS techniques **between investigator teams.**

*These studies are expansions of the original data set.

2. Learning curve


- Endometrial cancer

Variable	Traditional total abdominal n=56	Robotic-assisted n=36	Laparoscopic n=56	p Value
Operating time, min	136.9 (32.3) —	162.5 (53.0) ↑	192.3 (55.5) ↑	<.001
Estimated blood loss, mL	266.0 (145.1)	89.3 (45.4)	209.1 (91.8)	<.001
No. of lymph nodes retrieved				
Pelvic	30.8 (14.0) —	19.2 (7.9)	24.1 (11.8) ↓	<.001
Para-aortic	25.0 (13.7) —	12.9 (7.6)	20.9 (12.1) ↓	<.001

	Case 1-20	Case 21-40	Case 41-56	
Procedure	Mean (SD)	Mean (SD)	Mean (SD)	p Value
Operating time				
Traditional abdominal hysterectomy	139.7 (33.5)	133.3 (31.5)	NA	.56
Robotic-assisted hysterectomy	183.2 (69.0)	152.7 (39.8)	148.8 (36.7)	.09
Laparoscopic hysterectomy	196.7 (32.4)	181.4 (49.0)	200.9 (83.3)	.54
Pelvic lymph node retrieval				
Traditional abdominal hysterectomy	29.3 (15.6)	32.8 (12.2)	NA	.56
Robotic-assisted hysterectomy	18.0 (6.9)	22.2 (7.8)	17.2 (8.5)	.12
Laparoscopic hysterectomy	20.6 (9.7)	22.9 (11.6)	30.6 (12.7)	.03
Para-aortic lymph node retrieval				
Traditional abdominal hysterectomy	23.6 (15.0)	26.8 (12.2)	NA	.50
Robotic-assisted hysterectomy	12.8 (7.1)	16.2 (7.9)	10.2 (8.7)	.47
Laparoscopic hysterectomy	15.8 (7.2)	20.8 (11.1)	28.0 (15.5)	.01

- The learning curve of LS staging surgery seems to be **more difficult** than that of **open surgery**, even than **robotic surgery**.



- *Then, how many cases are enough?*



- 20 patients with LS hysterectomy and PLND (\pm PALNS) for early cancer : 13 cervical & 7 endometrial

- After a learning curve of 9 patients, a relevant improvement at least regarding the duration of the operation can be achieved.

- 70 patients with LS RH and PLND for early cervical cancer



- An extended learning period is required for LRHND.
- After a learning curve of **40 cases**, the surgeon may achieve a higher level of competence.

3. Adequacy of staging

Comprehensive Surgical Staging

KUMC

- Meta-analysis of 4 RCTs in early ovarian cancer
 - Benefits of adjuvant platinum-based chemotherapy
 - OS: HR 0.71; 95% CI 0.53 to 0.93
 - PFS: HR 0.67; 95% CI 0.53 to 0.84
 - But, optimally staged women were unlikely to benefit from adjuvant chemotherapy.
 - So, adjuvant chemotherapy is indicated when staging is considered to be inadequate.
- ➡ Hence, comprehensive surgical staging has **an important impact on the subsequent management**



Lymph Node Dissection/Sampling

	Pelvic lymph Nodes (n)			Para-aortic nodes (n)			Omental specimen (cm ³)		
	LPS	LPT	P	LPS	LPT	P	LPS	LPT	P
<i>Hua 2005</i>	25	27	NS	-	-	-	-	-	-
<i>Chi 2005</i>	12.3	14.7	NS	6.7	9.2	NS	186	347	0.09
<i>Ghezzi 2007</i>	25.2	25.1	0.96	6.5	7	0.78	-	-	-
<i>Park^a 2008</i>	13.7	19.3	0.052	8.9	6.4	0.187	-	-	-
<i>Park^b 2008</i>	27.2	33.9	0.079	6.6	8.8	0.324	160	274	0.113
<i>Park 2010[*]</i>	-	-	NS	-	-	NS	-	-	NS
<i>Park 2011[*]</i>	-	-	NS	-	-	NS	-	-	NS
<i>Lee 2011</i>	23.5	22.8	0.867	9.9 ↑	4.8	0.003	-	-	-

- Similar between LPS vs. LPT,
but, the result can be different according to **the surgeon's skill as well as intention** to achieve complete LND.

- But, Systematic retroperitoneal LND is **not uniformly** considered a standard staging procedure in all centers.
 - Because therapeutic effect of LND in women with early stage ovarian cancer is still debated, and associated risks and cost effectiveness.

Ex) In UK , NICE (National Institute for Health and Clinical Excellence) guideline

“Do not include systematic LND

as part of standard treatment in suspected stage I ovarian cancer”

- If a palpable abnormality, sampling from PLN ± PALN
- If there is no palpable abnormality, random sampling

Limitation on Lymphadenectomy

KUMC

- **But, palpation?**

: It is an inherent shortcoming of laparoscopy...

- Inability to palpate LN & other peritoneal surfaces

- However, intraoperative direct visualization and evaluation of nodes by palpation is inherently **subjective**.

Accuracy of Lymph Node Palpation for Each Surgeon Based on Years of Experience

Surgeon	N	TN	TP	FN	FP	Sens	Spec	PPV	NPV	Years exp
1	32	20	8	1	3	88%	87%	72%	95%	13
2	28	14	6	3	5	67%	74%	55%	82%	7
3	66	42	9	5	10	64%	81%	47%	89%	8
Total	126	76	23	9	18	72%	81%	56%	89%	

❖ **Conclusion:** LN palpation **has low sensitivity & positive predictive value** even when done by experienced GY oncologists.

Upstaging Rate

- LN yield & upstaging rate
: Potentially used as a surrogate marker for adequacy of staging
- But, the means of radiological assessment of metastasis prior to LS staging is variable within previously published studies.


	Study period	No. Case		Tumor upstaged, n (%)			Final diagnosis = stage I (n, %)	
		LPS	LPT	LPS	LPT	P	LPS	LPT
<i>Hua 2005</i>	2002-2004	10	11	0	0	-	10 (100)	11 (100)
<i>Ghezzi 2007</i>	2003-2006	15	19	4 (26.7)	6 (31.6)	1.0	11 (73.3)	13 (68.4)
<i>Park^a 2008</i>	2001-2006	17	19	1 (5.9)	6 (31.6)	0.092	16 (94.1)	13 (68.4)
<i>Park^b 2008</i>	2004-2007	19	33	4 (21)	7 (21.2)	0.936	15 (78.9)	26 (78.8)
<i>Lee 2011</i>	2005-2010	26	87	1 (3.8)	5 (5.7)	0.212	25 (96.2)	82 (94.3)

4. Visualization

Better Visualization due to Magnification

KUMC

- But, limitation on examination of these part:
 - Diaphragmatic peritoneum behind the liver & spleen, liver dome
 - Although isolated metastases to these areas are rare



**Picture: The Trocar (Official OnLine Video Journal of ISGE)*

Learning curve and pitfalls of a laparoscopic score to describe peritoneal carcinosis in advanced ovarian cancer

- ❖ Prospective study in **advanced** ovarian cancer
: Estimated the **agreement**
between a fellow in training & a senior surgeon
performing a LS score to describe peritoneal carcinosis

Parameter	Higher evaluation No. of cases	Lower evaluation No. of cases	Not evaluable No. of cases	Cohen's kappa	Disagreement (%)
Bowel infiltration	4	5	3	0.70	13.3
Mesenteral retraction	2	5	3	0.70	11.1
Omental cake	3	3	2	0.81	8.8
Stomach infiltration	2	1	5	0.84	8.8
Liver metastases	1	2	1	0.78	4.4
Diaphragmatic carcinosis	2	1	1	0.88	4.4
Peritoneal carcinosis	1	0	0	0.96	1.1

5. Tumor rupture

The clinical impact of intraoperative tumor rupture *is still debated*.

KUMC

- Laparoscopy has been associated with a higher rate of cyst rupture for apparently **benign** and **borderline tumors**

Ann Oncol 2005;16:403

- Intraoperative rupture of stage I ovarian cancer tumor
 - May result in upstaging from stage Ia or 1b to Ic
 - The most powerful **prognostic indicators of DFS** in stage
 - Grade & **tumor rupture** (HR: 2.65, 95% CI: 1.53-4.56)

Lancet 2001;20:176

	Study period	No. Case		Tumor size (cm)			Intra-operative tumor spillage, n (%)		
		LPS	LPT	LPS	LPT	<i>P</i>	LPS	LPT	<i>P</i>
<i>Hua 2005</i>	2002-2004	10	11				0	0	-
<i>Ghezzi 2007</i>	2003-2006	15	19				3 (20)	2 (10.5)	0.63
<i>Park^a 2008</i>	2001-2006	17	19	4.0	4.5	0.618	0	0	-
<i>Park^b 2008</i>	2004-2007	19	33	8.9	11.0	0.254	2 (10.5)	4 (12.1)	1.000
<i>Park 2010*</i>	2004-2008	40	76	-	-	-	-	-	NS
<i>Park 2011*</i>	2004-2010	84	128	-	-	-	-	-	NS
<i>Lee 2011</i>	2005-2010	26	87	9.1 ↓	14.0	0.010	0 ↓	13 (14.9)	0.037

- To properly assess these outcomes, future studies should clarify:
Clear description of technique & adjusting other factors (e.g. tumor size)

6. CO₂ pneumoperitoneum

Whether it enhances wound recurrence *remains unclear*.

KUMC

- **Possible mechanisms:**

- CO₂ has been shown to lower the peritoneal pH, which may activate enzymes that increase tumor cell mitosis & growth factor production.

Surg Endosc 2008;22:359

- Mechanical damage to the mesothelium
- Mechanical pressure to disseminate the cancer cells


Cancer 1999;86:770

➡ Stimulate port-site metastasis

- ❖ A recent meta-analysis: 20 RCTs involving 1,229 animals
 - Wound recurrence rate
 - Laparoscopy vs. Gasless laparoscopy
 - OR: 2.23, 95 % CI: 0.90–5.55, P=0.08
 - Laparoscopy vs. Laparotomy
 - OR: 0.97, 95 % CI: 0.31–3.00, P=0.08
 - Laparoscopy vs. (Gasless laparoscopy + Laparotomy)
 - OR:1.47, 95 % CI, 0.74–2.92; P=0.28
- ➡ CDP is **not** responsible for these tumors.

- First report of port-site metastases:
 - Found in a patient with *ovarian cancer* in 1978 *Endoscopy 1978;10:127–30*
- Port-site recurrence rate after laparoscopy: **1-16%**
 - **1.96%** in 796 women with ov/tubal/peritoneal ca by Zivanovic et al.
 - **Comparable rate** to laparotomy *Gynecol Oncol 2008;111:431–7*
- Maybe technique-related & limited mostly to **advanced stage**
 - **Nearly no case of** port-site metastasis in stage I
 - Suggested method to prevent:
 - (1) Using an endoscopic bag to retrieve intact specimens
 - (2) A layered closure of the trocar site

8. Oncological outcome - Survival



	Median F/U (mo, range)		PFS (n, %)			OS (n, %)		
	LPS	LPT	LPS	LPT	P	LPS	LPT	P
<i>Ghezzi 2007</i>	16 (4-34)	60 (32-108)	15 (100)	15 (78.9)	-	15 (100)	19 (100)	-
<i>Park^a 2008</i>	19 (5-56)	14 (5-61)	15 (88)	19 (100)	-	16 (94)	19 (100)	-
<i>Park^b 2008</i>	17 (2-40)	23 (1-44)	19 (100)	33 (100)	-	19 (100)	33 (100)	-
<i>Park 2010*</i>	-	-	37 (92)	71 (93)	0.876	38 (96)	71 (94)	0.841
<i>Park 2011*</i>	-	-	66 (78)	100 (78)	0.873	75 (89)	110 (86)	0.731
<i>Lee 2011</i>	12 (1-42)	25 (1-74)	26 (100)	79 (91)	0.195	-	-	-

<Average rate of survival in ov ca>

FIGO stage	OS (%)		
	1Y	2Y	5Y
IA	98.4	96.2	89.6
IB	100	93.9	86.1
IC	96.3	91.4	83.4

Int J Gynaecol Obstet
2006; 95:S161

* Case number:
IA (632),
IB (69),
IC (72)

Survival Outcome

- Laparoscopic surgery for early stage ovarian cancer *seems safe* with similar rate of tumor recurrence & overall survival compared to laparotomy.
- But, the available survival data have very low quality, hence it is *not possible draw any conclusions* regarding the relative effect of laparoscopic staging on ovarian cancer survival from the existing literature.

Staging in Early Ovarian Cancer

Variables	Laparoscopy Group (n = 26)	Laparotomy Group (n = 87)	P
Total hospital costs	9893 (3681)	8218 (3354)	0.031
Charge for stay	438 (87)	638 (183)	<0.001
Average operative cost	1998 (678)	1237 (465)	<0.001
Disposable instrument cost	1320 (452)	544 (276)	<0.001
Instrument depreciation cost	58	16	<0.001
Direct material cost	1469 (503)	340 (173)	<0.001
Labor cost	917 (426)	603 (200)	0.016


Values are given as median (range) in US dollars.

- **Hospital stay** (mean): 6.4 days in LPS vs. 12.4 days in LPT (p<0.001)

- Operation costs for LPS were significantly higher.
- Where bed costs are higher, this difference in cost might be eliminated.

Cost effectiveness in EM ca


- Multi-center RCT: 279 patients (TLH n=185 vs. TAH n=94)
- Previous perception:
 - LPS is more costly than open procedures.
- ➡ A major reason for the slow acceptance of LPS



- **Conclusion:** LPS appears to be preferable over LPT as \$52 will be saved per additional major complication-free patient.
- Higher costs were compensated by the lower costs for hospital stay.

10. Quality of life

- QoL can be assessed with various indicators.
 - Body image scale, pain score, role-physical score, physical functioning, role-emotional score, social functioning, mental health, etc.
- EM ca: RCT showed that the summed QoL dimensions **did not differ** between LPS vs. LPT.



- Retrospective, 28 cases with **EM & Cx cancer**

First 9 cases	“Laparoscopy” group		“Open” group <i>n</i> (%)	Phase 1 versus “open” group	Phase 2 versus “open” group
	Phase 1 <i>n</i> (%)	Phase 2 <i>n</i> (%)			
<u>Post-operation pain</u>				0.4	0.01
Until 1 week	4 (44)	10 (72.7)	13 (46.4)		
Until 1 month	3 (33)	3 (27.3)	14 (53.8)		
Until 1 year	2 (22)	0	6 (23.1)		
<u>Pain strength</u>				0.3	0.001
0–3	5 (55.5)	10 (90.9)	7 (26.9)		
4–6	3 (33)	0	12 (46.2)		
7–9	1 (11)	1 (9.1)	7 (26.9)		
<u>Return to normal life in</u>				0.3	0.003
2 weeks	0	8 (72.7)	3 (11.5)		
4 weeks	4 (44)	1 (9.1)	5 (19.2)		
6 weeks	2 (22)	1 (9.1)	11 (42.3)		
>6 weeks	3 (33)	1 (9.1)	7 (26.9)		
<u>Cosmetic satisfaction</u>				0.007	0.03
High	6 (66.7)	6 (54.5)	4 (15.4)		
Fair	3 (33)	4 (36.4)	12 (46.2)		
Low	0	1 (9.1)	10 (38.5)		

- Retrospective, 113 **Early Ovarian Cancer**
 - Postoperative pain score were lower in the LS group.

	Laparoscopy Group (n = 26)	Laparotomy Group (n = 87)	<i>P</i>
Port number, mean \pm SD, n	3.2 \pm 1.6		
Pain at 6 hours, median (range), score	5 (3–8)	6 (4–8)	<0.001
Pain on day 1	3 (1–6)	4 (3–5)	0.002
Pain on day 2	2 (1–6)	3 (2–4)	0.001
LNs, lymph nodes.			

Summary

- **Laparoscopic staging surgery for early stage ovarian cancer**
 - *Advantages* of minimally invasive surgery in surgical outcomes
; lower blood loss, faster recovery
 - *Feasible*, but wide regional variation in the skills, slow learning curve
 - **Operative time** is not longer, when performed by expert surgeons.
 - **Potential imitation in visualization**
 - *Safe*, but large well-designed data is lacking, especially for survival
 - *More costly, but more cost-effective*, considering lower post-operative complications & shorter hospital stay
 - *Higher quality of life* in terms of better cosmesis & less pain

Further Studies

- In endometrial cancer, a meta-analysis of RCTs demonstrated that laparoscopy is feasible & safe.
 - *It is possible that similar conclusions, in time, for stage I ovarian cancer* although the evidence for this is not currently enough.
- Future studies
 - Subgroup according to LN dissection or sampling
 - Detailed outcomes: OS, PFS, patient satisfaction, quality of life, costs, complications (intra-, post-operative), use of adjuvant chemotherapy
- Major barrier to conducting RCTs
 - Recruiting sufficient numbers of participants
 - Standardizing the quality of the surgery & skill of the surgeons

Laparoscopy-related Trials

KUMC

Protocol	Title	Status/ Year Published
KGOG 3028	Retrospective-Laparoscopic Surgery in Epithelial Ovarian Cancer	Active
LACC = KGOG 1031	A Phase III Randomized Clinical Trial of Laparoscopic or Robotic Radical Hysterectomy versus Abdominal Radical Hysterectomy in Patients with Early Stage Cervical Cancer	Active
GOG-LAP2	Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer	2011
GOG-9402	Laparoscopic staging in patients with incompletely staged cancers of the uterus , ovary , fallopian tube , and primary peritoneum	2007
GOG-9206	Feasibility of laparoscopic management of presumed stage I endometrial carcinoma and assessment of accuracy of myoinvasion estimates by frozen section	2006
GOG-9207	Laparoscopic retroperitoneal lymphadenectomy followed by immediate laparotomy for women with cervical cancer	2004



Thank you for you attention.

